Parkersburg WTAP-TV on MSN
West Virginia Parkinson’s and Movement Disorder Symposium
The Mid-Ohio Valley Parkinson’s Support Group’s Parkinson’s and Movement Disorder Symposium is an educational event for those ...
Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
Alterity Therapeutics (ASX:ATH) CEO Dr David Stamler presented new analyses from the phase II double-blinded ATH434-201 trial in MSA, showing positive effects on slowing disease progression and ...
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
Detailed price information for Alterity Therapeutics Ltd ADR (ATHE-Q) from The Globe and Mail including charting and trades.
Drug developers today have released a slew of announcements updating their programs – and the message is slow but steady ...
InvestorsHub on MSN
Alterity Therapeutics Shares Edge Higher After Encouraging MSA Trial Results
Shares of Alterity Therapeutics Ltd (NASDAQ:ATHE) climbed 3.3% in premarket trading on Thursday after the company unveiled ...
CND Life Sciences, Inc. (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and ...
On October 13, GemVax & KAEL announced that it held a plaque unveiling ceremony for the "International Progressive ...
Investing.com -- Alterity Therapeutics Ltd (NASDAQ:ATHE) stock rose 3.3% in premarket trading Thursday following the company’s presentation of positive data from its Phase 2 clinical trial for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback